AAPL   319.28 (+0.32%)
MSFT   182.74 (+0.74%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
BABA   206.92 (+3.72%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
AMD   53.80 (+3.98%)
T   30.81 (-0.80%)
GILD   77.83 (+3.33%)
DIS   117.23 (+0.41%)
NFLX   419.73 (+1.52%)
BA   145.11 (-3.14%)
AAPL   319.28 (+0.32%)
MSFT   182.74 (+0.74%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
BABA   206.92 (+3.72%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
AMD   53.80 (+3.98%)
T   30.81 (-0.80%)
GILD   77.83 (+3.33%)
DIS   117.23 (+0.41%)
NFLX   419.73 (+1.52%)
BA   145.11 (-3.14%)
AAPL   319.28 (+0.32%)
MSFT   182.74 (+0.74%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
BABA   206.92 (+3.72%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
AMD   53.80 (+3.98%)
T   30.81 (-0.80%)
GILD   77.83 (+3.33%)
DIS   117.23 (+0.41%)
NFLX   419.73 (+1.52%)
BA   145.11 (-3.14%)
AAPL   319.28 (+0.32%)
MSFT   182.74 (+0.74%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
BABA   206.92 (+3.72%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
AMD   53.80 (+3.98%)
T   30.81 (-0.80%)
GILD   77.83 (+3.33%)
DIS   117.23 (+0.41%)
NFLX   419.73 (+1.52%)
BA   145.11 (-3.14%)
Log in

NASDAQ:VRCAVerrica Pharmaceuticals Stock Price, Forecast & News

$11.47
-0.73 (-5.98 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.28
Now: $11.47
$12.32
50-Day Range
$9.97
MA: $10.98
$13.86
52-Week Range
$6.79
Now: $11.47
$18.67
Volume11,308 shs
Average Volume40,886 shs
Market Capitalization$296.04 million
P/E RatioN/A
Dividend YieldN/A
Beta2.46
Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company was founded in 2013 and is headquartered in West Chester, Pennsylvania.
Read More
Verrica Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRCA
CUSIPN/A
CIKN/A
Phone484-453-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.19 per share

Profitability

Net Income$-28,210,000.00

Miscellaneous

Employees16
Market Cap$296.04 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.

Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

How has Verrica Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VRCA stock has increased by 9.0% and is now trading at $11.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Verrica Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Verrica Pharmaceuticals.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Verrica Pharmaceuticals.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) announced its earnings results on Thursday, May, 7th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.01. View Verrica Pharmaceuticals' earnings history.

What price target have analysts set for VRCA?

2 equities research analysts have issued 12-month price targets for Verrica Pharmaceuticals' shares. Their forecasts range from $20.00 to $24.00. On average, they expect Verrica Pharmaceuticals' share price to reach $22.00 in the next year. This suggests a possible upside of 91.8% from the stock's current price. View analysts' price targets for Verrica Pharmaceuticals.

Has Verrica Pharmaceuticals been receiving favorable news coverage?

News coverage about VRCA stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Verrica Pharmaceuticals earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutVerrica Pharmaceuticals.

Are investors shorting Verrica Pharmaceuticals?

Verrica Pharmaceuticals saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 754,900 shares, a drop of 5.3% from the April 15th total of 797,100 shares. Based on an average daily volume of 67,900 shares, the days-to-cover ratio is presently 11.1 days. Currently, 5.9% of the company's stock are short sold. View Verrica Pharmaceuticals' Current Options Chain.

Who are some of Verrica Pharmaceuticals' key competitors?

What other stocks do shareholders of Verrica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include AbbVie (ABBV), Gilead Sciences (GILD), Aurora Cannabis (ACB), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Pfizer (PFE), Progenics Pharmaceuticals (PGNX), Exxon Mobil (XOM), Allergan (AGN) and Agile Therapeutics (AGRX).

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the following people:
  • Mr. Ted White, Pres, CEO & Director (Age 54)
  • Mr. Chris Degnan, Chief Financial Officer (Age 39)
  • Mr. Joe Bonaccorso, Chief Commercial Officer (Age 55)
  • Dr. Patrick Burnett M.D., Ph.D., Chief Medical Officer (Age 47)
  • Christopher G. Hayes, Sec.

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.82%), Kornitzer Capital Management Inc. KS (1.82%), Fosun International Ltd (1.26%), State Street Corp (0.91%), Geode Capital Management LLC (0.70%) and Nuveen Asset Management LLC (0.20%). Company insiders that own Verrica Pharmaceuticals stock include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White. View institutional ownership trends for Verrica Pharmaceuticals.

Which major investors are selling Verrica Pharmaceuticals stock?

VRCA stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Two Sigma Investments LP, Morgan Stanley, Squarepoint Ops LLC, Wells Fargo & Company MN, and UBS Group AG. View insider buying and selling activity for Verrica Pharmaceuticals.

Which major investors are buying Verrica Pharmaceuticals stock?

VRCA stock was acquired by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Geode Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., State Street Corp, Nuveen Asset Management LLC, Alliancebernstein L.P., BlackRock Inc., and Capital Investment Advisory Services LLC. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Paul B Manning, Sean Stalfort, and Ted White. View insider buying and selling activity for Verrica Pharmaceuticals.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $11.47.

How big of a company is Verrica Pharmaceuticals?

Verrica Pharmaceuticals has a market capitalization of $296.04 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is www.verrica.com.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.